弥散性血管内凝血 中国就医指南

Disseminated Intravascular Coagulation (DIC) is a life-threatening systemic thrombohemorrhagic disorder characterized by widespread activation of the coagulation cascade, leading to simultaneous microvascular thrombosis and consumption of platelets and clotting factors. This pathological process results in both organ ischemia due to microthrombi and severe bleeding from coagulopathy. DIC is not a primary disease but rather a secondary complication triggered by underlying conditions such as sepsis (especially gram-negative bacterial or fungal), severe trauma, major surgery, obstetric catastrophes (e.g., amniotic fluid embolism, placental abruption, eclampsia), malignancies (particularly acute promyelocytic leukemia and mucin-secreting adenocarcinomas), and severe inflammatory states including COVID-19-associated critical illness. Pathogenically, DIC arises from uncontrolled release of tissue factor and proinflammatory cytokines (e.g., TNF-α, IL-6), which overwhelm natural anticoagulant mechanisms (antithrombin, protein C/S system, tissue factor pathway inhibitor) and impair fibrinolysis—often resulting in either hyperfibrinolysis or, more commonly, hypofibrinolysis with persistent thrombus burden. Epidemiologically, DIC occurs in approximately 1% of all hospitalized patients but rises dramatically in intensive care units: it affects 20–50% of septic patients, 25–35% of trauma patients with shock, and up to 70% of patients with acute promyelocytic leukemia. Mortality remains high—ranging from 30% to 80% depending on etiology, speed of recognition, and comorbid burden—with sepsis-associated DIC carrying the worst prognosis. Key risk factors include advanced age, immunosuppression, multiorgan dysfunction, preexisting liver or renal failure, and delayed diagnosis. Clinically, DIC manifests heterogeneously: early signs may include petechiae, ecchymoses, mucosal bleeding, hematuria, or prolonged surgical wound oozing; later progression involves limb ischemia, acral cyanosis, digital necrosis, acute kidney injury, respiratory failure, or altered mental status due to cerebral microthrombosis. Laboratory hallmarks include progressive thrombocytopenia, elevated D-dimer and fibrin degradation products (FDPs), decreased fibrinogen, prolonged PT/aPTT, and schistocytes on peripheral smear. Quality of life impact is profound—even among survivors, long-term sequelae frequently include chronic fatigue, cognitive impairment, post-traumatic stress, limb amputations, and persistent organ dysfunction requiring rehabilitation or dialysis. Psychological burden on patients and families is substantial due to sudden clinical deterioration, ICU admission, invasive monitoring, and uncertainty around recovery. Early recognition using validated scoring systems (e.g., ISTH DIC score) and aggressive management of the underlying trigger are paramount. Supportive care—including judicious transfusion of platelets, cryoprecipitate, or fibrinogen concentrate—and targeted therapies (e.g., antithrombin replacement in deficiency states, recombinant human activated protein C in select cases—though withdrawn in many regions, or thrombomodulin under investigation) remain central. Unlike routine coagulopathies, DIC demands dynamic, individualized hemostatic support guided by serial laboratory assessment and clinical trajectory—not fixed protocols.

# 弥散性血管内凝血（DIC）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：早期DIC、原发病可控（如感染、产科急症）、无活动性大出血或器官衰竭者。

• •基础支持：抗感染（头孢曲松等）、纠正休克、维持血压/氧合：800–3,500元/日
• •抗凝治疗（低分子肝素皮下注射）：需监测APTT、FIB、D-二聚体（每日检验费：260–420元）；疗程5–14天，药费1,200–4,800元
• •替代治疗（按需）：新鲜冰冻血浆（200ml/袋，420–580元）、冷沉淀（1单位，380–520元）、血小板（1治疗量，1,100–1,600元）

二、介入/核心干预方案

适用人群：继发于恶性肿瘤、严重创伤或顽固性出血，需快速控制凝血紊乱。

• •血浆置换（TPE）：单次置换1.0–1.5倍血浆量，含管路耗材、白蛋白补充；4,200–6,800元/次（含术前凝血功能+肝肾功检查费320元）
• •连续性肾脏替代治疗（CRRT）联合抗凝管理：用于合并AKI的DIC患者，12,000–22,000元/日（含滤器、抗凝监测及血气电解质检测）

三、特殊复杂方案

晚期/耐药/多器官衰竭DIC：联合靶向治疗（如重组人血栓调节蛋白，18,000–25,000元/支，通常1–3支）、重症监护（ICU日均费用12,000–28,000元），总疗程费用常超15万–50万元。

方案快速选择指南

• •预算≤3万元：首选规范抗感染+低分子肝素+FFP替代（三甲医院标准路径）
• •中高风险/进展期：加用血浆置换（单次≤7千元，性价比最优）
• •危重多器官衰竭：转入血液科ICU启动CRRT+靶向药物，需预筹≥30万元